Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZ) (the "Company") today announced that it is raising US$7,560,000 in gross proceeds in a registered direct offering to a single healthcare dedicated institutional investor in...

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the remaining 8,064 Series B Common Share Purchase Warrants (the "Series B Warrants") issued in connection with the Company's March 2015...

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company") today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the Aegis Capital Corp.

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the Rodman & Renshaw 18th Annual...

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it is expanding its promotion of APIFINY ®, the only cancer-specific, non-PSA blood test available to assess the risk for the...

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY ®, the only cancer specific, non-PSA blood test...

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("Aeterna Zentaris" or the "Company") today announced that it has mailed a Notice of Meeting and Management Information Circular (the "Meeting Materials") to the shareholders...

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that it has started promoting APIFINY ®, the only cancer specific, non-PSA blood test for the evaluation of the risk of prostate cancer, in...